Eli Lilly Research and Development Expenses 2010-2024 | LLY

Eli Lilly annual/quarterly research and development expenses history and growth rate from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • Eli Lilly research and development expenses for the quarter ending September 30, 2024 were $2.734B, a 13.49% increase year-over-year.
  • Eli Lilly research and development expenses for the twelve months ending September 30, 2024 were $10.531B, a 20.4% increase year-over-year.
  • Eli Lilly annual research and development expenses for 2023 were $9.313B, a 29.52% increase from 2022.
  • Eli Lilly annual research and development expenses for 2022 were $7.191B, a 3.75% increase from 2021.
  • Eli Lilly annual research and development expenses for 2021 were $6.931B, a 15.97% increase from 2020.
Eli Lilly Annual Research and Development Expenses
(Millions of US $)
2023 $9,313
2022 $7,191
2021 $6,931
2020 $5,976
2019 $5,595
2018 $5,051
2017 $5,096
2016 $5,310
2015 $4,796
2014 $4,734
2013 $5,531
2012 $5,278
2011 $5,021
2010 $4,884
2009 $4,327
Eli Lilly Quarterly Research and Development Expenses
(Millions of US $)
2024-09-30 $2,734
2024-06-30 $2,711
2024-03-31 $2,523
2023-12-31 $2,563
2023-09-30 $2,409
2023-06-30 $2,357
2023-03-31 $1,985
2022-12-31 $1,996
2022-09-30 $1,803
2022-06-30 $1,782
2022-03-31 $1,610
2021-12-31 $1,898
2021-09-30 $1,705
2021-06-30 $1,655
2021-03-31 $1,672
2020-12-31 $1,729
2020-09-30 $1,465
2020-06-30 $1,390
2020-03-31 $1,392
2019-12-31 $1,581
2019-09-30 $1,381
2019-06-30 $1,402
2019-03-31 $1,231
2018-12-31 $1,392
2018-09-30 $1,281
2018-06-30 $1,271
2018-03-31 $1,108
2017-12-31 $1,226
2017-09-30 $1,340
2017-06-30 $1,272
2017-03-31 $1,258
2016-12-31 $1,517
2016-09-30 $1,236
2016-06-30 $1,336
2016-03-31 $1,221
2015-12-31 $1,444
2015-09-30 $1,143
2015-06-30 $1,170
2015-03-31 $1,039
2014-12-31 $1,186
2014-09-30 $1,243
2014-06-30 $1,195
2014-03-31 $1,109
2013-12-31 $1,475
2013-09-30 $1,377
2013-06-30 $1,330
2013-03-31 $1,348
2012-12-31 $1,463
2012-09-30 $1,343
2012-06-30 $1,321
2012-03-31 $1,152
2011-12-31 $1,355
2011-09-30 $1,281
2011-06-30 $1,261
2011-03-31 $1,124
2010-12-31 $1,438
2010-09-30 $1,220
2010-06-30 $1,187
2010-03-31 $1,039
2009-12-31 $1,217
2009-09-30 $1,122
2009-06-30 $1,040
2009-03-31 $947
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $790.248B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $489.545B 35.30
Johnson & Johnson (JNJ) United States $373.278B 15.14
AbbVie (ABBV) United States $308.242B 16.23
Merck (MRK) United States $254.810B 16.93
Novartis AG (NVS) Switzerland $215.989B 14.36
AstraZeneca (AZN) United Kingdom $200.887B 17.90
Pfizer (PFE) United States $148.702B 10.17
Sanofi (SNY) $128.465B 11.64
Innoviva (INVA) United States $1.259B 10.48